JP6001655B2 - 併用療法 - Google Patents
併用療法 Download PDFInfo
- Publication number
- JP6001655B2 JP6001655B2 JP2014516405A JP2014516405A JP6001655B2 JP 6001655 B2 JP6001655 B2 JP 6001655B2 JP 2014516405 A JP2014516405 A JP 2014516405A JP 2014516405 A JP2014516405 A JP 2014516405A JP 6001655 B2 JP6001655 B2 JP 6001655B2
- Authority
- JP
- Japan
- Prior art keywords
- pme
- cancer
- sirna
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
を有する化合物との組合せを医薬として提供し、
表4。スタウロスポリンの試験した類似体/誘導体の例。PME−1特異的dsRNAによるトランスフェクション、及び異なるスタウロスポリン類似体/誘導体の指示された濃度による処理の後の、T98Gグリア芽細胞腫細胞でのアポトーシスの核断片化の量(増強%)を示す。
真核生物の細胞培養及び小分子干渉RNA(siRNA)のトランスフェクション:この試験のために、本発明者らはT98G、U118MG、U251MG及びU87MGヒトグリア芽細胞腫細胞系を用いた。T98G及びU251MG細胞はイーグルのMEM培地で、U118MGはDMEM培地(Sigma−Aldrich)で、U87MGはDMEM/F−12培地(Gibco Products、Invitrogen)で、37℃で5%CO2の加湿雰囲気内で培養し、培地には、10%熱不活性化FCS及びペニシリン(100単位/mL)−ストレプトマイシン(100Ag/mL)を加えた。小分子干渉RNA(siRNA)のトランスフェクションは、製造業者の指示に従って、リポフェクトアミンRNAiMAX試薬(Invitrogen)で実施した。リバーストランスフェクションが96ウェルプレートで実施されたCellTiter−glo及びカスパーゼ−gloアッセイを除いて、全ての実験でトランスフェクションはフォワードトランスフェクションプロトコルを用いて実施された。以下のsiRNA配列が用いられた:スクランブルされた(5’−GUA ACA AUG AGA GCA CGG C−3’;配列番号40)、PME−1(5’−GGA AGU GAG UCU AUA AGC A−3’;配列番号1)、PME−1(5’−UCA UAG AGG AAG AAG AAG A−3’;配列番号2)又はPME−1(5’−AGG UCA AGA AUC CUG AAG A−3’;配列番号3)、CIP2A(5’−CUG UGG UUG UGU UUG CAC U−3’;配列番号41)、PPP2R2A(5’−CUG CAG AUG AUU UGC GGA U−3’;配列番号42)、PPP2R2C(5’−ACC GCU CAU UCU UCU CGG AAA −3’;配列番号43)、PPP2R3B(5’−CAC GUG UCU CUG UCA CGU G−3’;配列番号44)、PPP2R5A(5’−CUG UAU CAU GGC CAU AGU A−3’;配列番号45)及びPPP2R5B(5’−CCG CAU GAU CUC AGU GAA U−3’;配列番号46)。
結果
配列番号2 PME−1 siRNA
配列番号3 PME−1 siRNA
配列番号4 PME−1 siRNA
配列番号5 PME−1 siRNA
配列番号6 PME−1 siRNA
配列番号7 PME−1 siRNA
配列番号8 PME−1 siRNA
配列番号9 PME−1 siRNA
配列番号10 PME−1 siRNA
配列番号11 PME−1 siRNA
配列番号12 PME−1 siRNA
配列番号13 PME−1 siRNA
配列番号14 PME−1 siRNA
配列番号15 PME−1 siRNA
配列番号16 PME−1 siRNA
配列番号17 PME−1 siRNA
配列番号18 PME−1 siRNA
配列番号19 PME−1 siRNA
配列番号20 PME−1 siRNA
配列番号21 PME−1 siRNA
配列番号22 PME−1 siRNA
配列番号23 PME−1 siRNA
配列番号24 PME−1 siRNA
配列番号25 PME−1 siRNA
配列番号26 PME−1 siRNA
配列番号27 PME−1 siRNA
配列番号28 PME−1 siRNA
配列番号29 PME−1 siRNA
配列番号30 PME−1 siRNA
配列番号31 PME−1 siRNA
配列番号32 PME−1 siRNA
配列番号33 PME−1 siRNA
配列番号34 PME−1 siRNA
配列番号35 PME−1 siRNA
配列番号36 PME−1 siRNA
配列番号37 PME−1 shRNA
配列番号38 PME−1 shRNA
配列番号39 PME−1 shRNA
配列番号40 Scrambled siRNA
配列番号41 CIP2A siRNA
配列番号42 PPP2R2A siRNA
配列番号43 PPP2AR2C siRNA
配列番号44 PPP2R3B siRNA
配列番号45 PPP2R5A siRNA
配列番号46 PPP2R5B siRNA
Claims (9)
- 少なくとも1種類のPME−1サイレンシング剤と、式(I)
(式中、
R’は、H又はアルキルであり;
R’’は、H又はアルコキシであり;
R1及びR2は、Hであるか一緒にオキソを形成し;
R3及びR4は、独立してH、OHであるか一緒にオキソを形成し:
R5、R6、R6’、R7及びR8は、H、アルキル、アルコキシ、ヒドロキシ、ヒドロキシルアルキル、アルコキシカルボニル又はモノ−及びジアルキルアミノからなる群から独立して選択され;
Xは、CH2又はOであり;
nは、0又は1である)
の化合物とを組合せて含む医薬。 - 少なくとも1種類のPME−1サイレンシング剤と、
の化合物とを組合せて含む医薬。 - PME−1サイレンシング剤が、siRNA分子、DsiRNA分子、人工miRNA前駆体、shRNA分子、アンチセンスオリゴヌクレオチド、リボザイム、及びPP2Acに対するPME−1機能を阻止する作用剤からなる群から選択される、請求項1又は2に記載の医薬。
- PME−1サイレンシング剤が、配列番号1〜39からなる群から選択される核酸配列を含む、請求項1又は2に記載の医薬。
- 式(I)の化合物が、
からなる群から選択される、請求項1に記載の医薬。 - 過剰増殖性疾患の処置に用いるための、請求項1又は2に記載の医薬。
- 前記過剰増殖性疾患が、乾癬、心筋肥大、良性腫瘍、固形がん及び血液がんからなる群から選択される、請求項6に記載の医薬。
- 前記固形がんが、頭頸部扁平上皮癌、結腸がん、胃がん、乳がん、卵巣がん、前立腺がん、子宮頸がん、脳がん、神経膠腫、星状細胞腫及びグリア芽細胞腫からなる群から選択される、請求項7に記載の医薬。
- 請求項1から8までのいずれか一項に記載の医薬及び少なくとも1種の薬学的に許容される担体を含む医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161499750P | 2011-06-22 | 2011-06-22 | |
FI20115640 | 2011-06-22 | ||
US61/499,750 | 2011-06-22 | ||
FI20115640A FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Yhdistelmähoito |
PCT/FI2012/050618 WO2012175798A2 (en) | 2011-06-22 | 2012-06-15 | Combination therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014523426A JP2014523426A (ja) | 2014-09-11 |
JP2014523426A5 JP2014523426A5 (ja) | 2015-07-30 |
JP6001655B2 true JP6001655B2 (ja) | 2016-10-05 |
Family
ID=44206849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014516405A Expired - Fee Related JP6001655B2 (ja) | 2011-06-22 | 2012-06-15 | 併用療法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9476050B2 (ja) |
EP (1) | EP2723450B1 (ja) |
JP (1) | JP6001655B2 (ja) |
CN (1) | CN103781514A (ja) |
CA (1) | CA2839807A1 (ja) |
DK (1) | DK2723450T3 (ja) |
FI (1) | FI20115640A0 (ja) |
WO (1) | WO2012175798A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104755936B (zh) * | 2012-08-30 | 2018-04-27 | 图尔库大学 | 选择个性化脑癌疗法的方法 |
US9663789B2 (en) * | 2013-04-26 | 2017-05-30 | Medical Diagnostic Laboratories, Llc | PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition |
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
EA038551B1 (ru) | 2015-12-17 | 2021-09-14 | Дзе Джонс Хопкинс Юниверсити | Способ лечения или профилактики системного склероза |
EA201892260A1 (ru) | 2016-04-07 | 2019-03-29 | Дзе Джонс Хопкинс Юниверсити | Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
AU2003290083A1 (en) * | 2002-08-13 | 2004-03-11 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas |
JP2006512906A (ja) | 2002-09-28 | 2006-04-20 | マサチューセッツ インスティチュート オブ テクノロジー | インフルエンザ治療剤 |
US20040077083A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
US20040077084A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20090182134A1 (en) * | 2002-11-14 | 2009-07-16 | Dharmacon, Inc. | siRNA targeting phosphatases |
CA2523517C (en) * | 2003-04-25 | 2013-07-30 | Dana-Farber Cancer Institute, Inc. | Bcl2l12 polypeptide activators and inhibitors |
US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
WO2005011598A2 (en) | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
US20080021198A1 (en) | 2005-10-12 | 2008-01-24 | Yigong Shi | Modulators of protein phosphatase 2A and PP2A methyl esterase |
GB0612542D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
US20090274682A1 (en) | 2008-02-05 | 2009-11-05 | The Trustees Of Princeton University | Demethylation and inactivation of protein phosphatase 2a |
WO2010091140A1 (en) | 2009-02-04 | 2010-08-12 | Bipar Sciences, Inc. | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
-
2011
- 2011-06-22 FI FI20115640A patent/FI20115640A0/fi not_active Application Discontinuation
-
2012
- 2012-06-15 WO PCT/FI2012/050618 patent/WO2012175798A2/en active Application Filing
- 2012-06-15 JP JP2014516405A patent/JP6001655B2/ja not_active Expired - Fee Related
- 2012-06-15 EP EP12767025.5A patent/EP2723450B1/en not_active Not-in-force
- 2012-06-15 CA CA2839807A patent/CA2839807A1/en not_active Abandoned
- 2012-06-15 CN CN201280040838.2A patent/CN103781514A/zh active Pending
- 2012-06-15 US US14/128,342 patent/US9476050B2/en not_active Expired - Fee Related
- 2012-06-15 DK DK12767025.5T patent/DK2723450T3/en active
Also Published As
Publication number | Publication date |
---|---|
EP2723450B1 (en) | 2016-05-18 |
WO2012175798A2 (en) | 2012-12-27 |
FI20115640A0 (fi) | 2011-06-22 |
WO2012175798A3 (en) | 2013-04-11 |
EP2723450A2 (en) | 2014-04-30 |
DK2723450T3 (en) | 2016-07-04 |
US20140135377A1 (en) | 2014-05-15 |
JP2014523426A (ja) | 2014-09-11 |
CA2839807A1 (en) | 2012-12-27 |
US9476050B2 (en) | 2016-10-25 |
CN103781514A (zh) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9968630B2 (en) | Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function | |
US10813934B2 (en) | Sirtuin modulators as inhibitors of cytomegalovirus | |
JP6001655B2 (ja) | 併用療法 | |
WO2011097221A2 (en) | Methods of promoting tissue growth and tissue regeneration | |
US10094834B2 (en) | Method of selecting individualized brain cancer therapy | |
JP6393682B2 (ja) | 併用療法iii | |
WO2017089347A1 (en) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas | |
Yousefi et al. | Knockdown of HSF1 sensitizes resistant prostate cancer cell line to chemotherapy | |
WO2014092572A1 (en) | Improved methods for cancer treatment with a genotoxic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150609 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150609 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160708 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160823 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160901 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6001655 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |